The role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes

Diabetic Medicine, Supplement

Volumn 21, Issue 4, 2004, Pages 8-11

  Wild, S ^a   Byrne, C D ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BENDROFLUMETHIAZIDE; BEZAFIBRATE; BISOPROLOL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LISINOPRIL; NICOTINIC ACID; OMEGA 3 FATTY ACID; SIMVASTATIN; STATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DYSLIPIDEMIA; EXERCISE; FLUSHING; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 4544258338     PISSN: 14665468     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.1424-5.x     Document Type: Review

References (20)

1. Wilson PW, Kannel WB, Anderson KM. Lipids, glucose intolerance and vascular disease: the Framingham Study. Atherosclerosis 1985; 13: 1-11.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Eng J Med 1998; 339: 229-234.
3. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. Br Med J 2002; 324: 939-942.
4. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.
5. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). Br Med J 1998; 316: 823-828.
6. Third Report of the National Cholesterol Education Panel Expert Report on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), NIH Publication no. 02-5215. National Heart, Lung, and Blood Institute, National Institutes of Health, 2002.
7. Huttunen JK, Manninen V, Manttari M, Koskinen P, Romo M, Tenkanen L et al. The Helsinki Heart Study: central findings and clinical implications. Ann Med 1991; 23: 155-159.
8. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
9. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000; 247: 563-569.
10. Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003; 91: 956-960.
11. Feher MD, Foxton J, Banks D, Lant AF, Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J 1995; 74: 14-17.
12. Feher MD, Langley-Hawthorne CE, Byrne CD. Cost-outcome benefits of fibrate therapy in type 2 diabetes. Br J Diabetes Vasc Dis 2003; 3: 124-130.
13. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. New Engl J Med 1985; 312: 1205-1209.
14. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R et al. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-1903.
15. Thies F, Garry JMC, Yaqoob P, Rerkasem K, Williams J, Shearman CP et al. Association of n-3 polyunsatutated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003; 361: 477-485.
16. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82: 737-743.
17. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D et al., the Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162: 1568-1576.
18. Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991; 40: 549-51.
19. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592.
20. Zhao XQ, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 2004; 93: 307-312.